These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4006933)

  • 21. Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.
    Jones RN; Barry AL; Thornsberry C
    Rev Infect Dis; 1982; 4 Suppl():S366-73. PubMed ID: 6294785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacteriological comparison of the activities of ceftriaxone, a new long-acting cephalosporin, with those of other new cephalosporins.
    Arisawa M; Ohshima J; Ohsawa E; Maruyama HB; Sekine Y; Mitsuhashi S
    Chem Pharm Bull (Tokyo); 1982 Jul; 30(7):2544-54. PubMed ID: 6291792
    [No Abstract]   [Full Text] [Related]  

  • 23. In-vitro activity of Sch 29482, MK 0787, ceftriaxone and seven other antimicrobials against 840 separate clinical isolates.
    Pierson CL; Schaberg DR; Fekety FR; McClatchey KD
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():79-89. PubMed ID: 6277844
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination of ceftizoxime with azlocillin, mezlocillin, piperacillin and ticarcillin.
    Neu HC
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():63-8. PubMed ID: 6296031
    [No Abstract]   [Full Text] [Related]  

  • 25. Antimicrobial activity of ceftriaxone: a review.
    Cleeland R; Squires E
    Am J Med; 1984 Oct; 77(4C):3-11. PubMed ID: 6093515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydrolytic model for cefotaxime and ceftriaxone resistance in beta-lactamase-derepressed Enterobacter cloacae.
    Livermore DM; Riddle SJ; Davy KW
    J Infect Dis; 1986 Mar; 153(3):619-22. PubMed ID: 3485161
    [No Abstract]   [Full Text] [Related]  

  • 27. Interpretation of susceptibility testing of ceftriaxone.
    Squires E; Cleeland R; Christenson J; Boehni E
    Am J Med; 1984 Oct; 77(4C):12-6. PubMed ID: 6093512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceftriaxone against gram-negative and gram-positive bacteria: bactericidal and post-antibiotic effect.
    Ravizzola G; Bonfanti C; Savoldi E; Turano A
    Chemioterapia; 1985 Jun; 4(3):204-8. PubMed ID: 3875430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative experimental antibacterial activity of ceftriaxone (Ro 13-9904).
    Böhni E
    Chemioterapia; 1984 Feb; 3(1):25-32. PubMed ID: 6100173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Sensitivity to cefotiam of 494 hospital bacterial strains. Determination of minimal inhibitory concentration and comparison with other beta-lactams].
    Reynaud A; Desnoes M; Derriennic M; Courtieu AL
    Pathol Biol (Paris); 1985 May; 33(5):313-9. PubMed ID: 3929216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefotaxime and desacetylcefotaxime: an example of advantageous antimicrobial metabolism.
    Chin NX; Neu HC
    Diagn Microbiol Infect Dis; 1984 Jun; 2(3 Suppl):21S-31S. PubMed ID: 6086215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in-vitro activity and mode of action of ceftriaxone (Ro 13-9904), a new highly potent cephalosporin.
    Hall MJ; Westmacott D; Wong-Kai-In P
    J Antimicrob Chemother; 1981 Sep; 8(3):193-203. PubMed ID: 6270051
    [No Abstract]   [Full Text] [Related]  

  • 33. Antimicrobial activity of cefotiam combinations against Enterobacteriaceae moderately susceptible or resistant to this new cephalosporin.
    Husson MO; Izard D; Leclerc H
    Drugs Exp Clin Res; 1986; 12(4):325-7. PubMed ID: 3459642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interpretation criteria for sensitivity testing of ceftriaxone in agar diffusion test according to the DIN 58940 method.
    Grimm H
    Chemotherapy; 1984; 30(1):49-53. PubMed ID: 6319090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.
    Richards DM; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Jun; 27(6):469-527. PubMed ID: 6329638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sensitivity of 300 strains of gram-negative bacteria to cefotaxime].
    Ben Redjeb S; Salah N; Ennaifar M; Bissardon O; Boujnah A
    Tunis Med; 1982; 60(1):55-8. PubMed ID: 6293131
    [No Abstract]   [Full Text] [Related]  

  • 37. Potencies of ceftriaxone and cefotaxime in a single chamber pharmacokinetic system simulating their in vivo half-lives.
    Unowsky J; Sattler J; Patel IH
    Chemotherapy; 1989; 35(5):338-44. PubMed ID: 2676404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cefmenoxime: in vitro activity.
    Stamm JM
    Am J Med; 1984 Dec; 77(6A):1-3. PubMed ID: 6097114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro study of the synergistic effect of cefmenoxime-aminoglycoside combinations apropos of 148 strains of Enterobacteriaceae].
    Husson MO; Izard D; Bryskier A; Leclerc H
    Pathol Biol (Paris); 1984 May; 32(5):396-8. PubMed ID: 6330651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.